About: Teprotumumab

An Entity of Type: monoclonal antibody, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org

Teprotumumab, sold under the brand name Tepezza, is a medication used to treat adults with thyroid eye disease, a rare condition where the muscles and fatty tissues behind the eye become inflamed, causing the eyes to bulge outwards. It is a human monoclonal antibody developed by Genmab and Roche for tumour treatment but was later researched by River Vision Development Corporation and Horizon Therapeutics to be used for ophthalmic uses. It binds to IGF-1R.

Property Value
dbo:abstract
  • Teprotumumab, sold under the brand name Tepezza, is a medication used to treat adults with thyroid eye disease, a rare condition where the muscles and fatty tissues behind the eye become inflamed, causing the eyes to bulge outwards. The most common side effects are muscle spasm, nausea, hair loss, diarrhea, fatigue, high blood sugar, hearing loss, dry skin, altered sense of taste and headache. Teprotumumab should not be used if pregnant, and women of child-bearing potential should have their pregnancy status verified prior to beginning treatment and should be counseled on pregnancy prevention during treatment and for six months following the last dose. It is a human monoclonal antibody developed by Genmab and Roche for tumour treatment but was later researched by River Vision Development Corporation and Horizon Therapeutics to be used for ophthalmic uses. It binds to IGF-1R. Teprotumumab was approved for use in the United States in January 2020. The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication. (en)
  • Тепротумумаб — лекарственный препарат, моноклональное антитело для лечения . Одобрен для применения: США (2020). (ru)
dbo:alternativeName
  • Tepezza (en)
dbo:casNumber
  • 1036734-93-6
dbo:chEMBL
  • 1743079
dbo:drugbank
  • DB06343
dbo:fdaUniiCode
  • Y64GQ0KC0A
dbo:kegg
  • D09680
dbo:wikiPageExternalLink
dbo:wikiPageID
  • 33024157 (xsd:integer)
dbo:wikiPageLength
  • 13072 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID
  • 1120166425 (xsd:integer)
dbo:wikiPageWikiLink
dbp:atcPrefix
  • L04 (en)
dbp:atcSuffix
  • AA53 (en)
dbp:c
  • 6476 (xsd:integer)
dbp:casNumber
  • 1036734 (xsd:integer)
dbp:chembl
  • 1743079 (xsd:integer)
dbp:chemspiderid
  • none (en)
dbp:dailymedid
  • Teprotumumab (en)
dbp:drugbank
  • DB06343 (en)
dbp:h
  • 10012 (xsd:integer)
dbp:kegg
  • D09680 (en)
dbp:legalUs
  • Rx-only (en)
dbp:mabType
  • mab (en)
dbp:n
  • 1748 (xsd:integer)
dbp:o
  • 2000 (xsd:integer)
dbp:routesOfAdministration
dbp:s
  • 40 (xsd:integer)
dbp:source
  • u (en)
dbp:synonyms
  • Teprotumumab-trbw, RG-1507 (en)
dbp:target
dbp:tradename
  • Tepezza (en)
dbp:type
  • mab (en)
dbp:unii
  • Y64GQ0KC0A (en)
dbp:verifiedfields
  • changed (en)
dbp:verifiedrevid
  • 470602132 (xsd:integer)
dbp:watchedfields
  • changed (en)
dbp:wikiPageUsesTemplate
dcterms:subject
gold:hypernym
rdf:type
rdfs:comment
  • Тепротумумаб — лекарственный препарат, моноклональное антитело для лечения . Одобрен для применения: США (2020). (ru)
  • Teprotumumab, sold under the brand name Tepezza, is a medication used to treat adults with thyroid eye disease, a rare condition where the muscles and fatty tissues behind the eye become inflamed, causing the eyes to bulge outwards. It is a human monoclonal antibody developed by Genmab and Roche for tumour treatment but was later researched by River Vision Development Corporation and Horizon Therapeutics to be used for ophthalmic uses. It binds to IGF-1R. (en)
rdfs:label
  • Teprotumumab (en)
  • Тепротумумаб (ru)
owl:sameAs
prov:wasDerivedFrom
foaf:isPrimaryTopicOf
is dbo:product of
is dbo:wikiPageRedirects of
is dbo:wikiPageWikiLink of
is foaf:primaryTopic of
Powered by OpenLink Virtuoso    This material is Open Knowledge     W3C Semantic Web Technology     This material is Open Knowledge    Valid XHTML + RDFa
This content was extracted from Wikipedia and is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License